Would you like to participate in a research program or do you know someone who may be interested?
The best way to improve understanding of the cause of a disease and to develop new and approved treatments is through Clinical Research. In addition to providing expert and compassionate care, experimental therapeutics designed to test novel therapeutic approaches that provide symptomatic relief as well as potentially slow the progression of the disease, is one of the primary missions in the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine. Patients can help by participating in clinical trials, some of which are listed below.
Many of our studies are placebo-controlled studies. This means that the medication being tested is compared to an inactive substance (“sugar-pill”). Patients will be informed of all known risks and benefits and will have an opportunity to discuss with the movement disorders specialists which studies may be most appropriate.
If interested in participating in one of the clinical studies listed below, patients or their referring physicians can contact Christine Hunter, R.N., at 713-798-3951 or e-mail her at .
The PDCMDC is currently conducting research in the following clinical areas:
Early Parkinson's disease: Patients who have never been treated with anti-Parkinson medications or those who are receiving Eldepryl (MAO-B), amantadine (NMDA antagonist) or anticholinergic therapy and have been on a stable dose for about one month can participate in clinical trials of several new medications designed to treat symptoms, delay the need for L-dopa, and to slow the progression of the disease.
Parkinson's disease (PD): Patients with PD who have a first through third degree relative also with PD, can participate in a genetic study of PD. An example of a first-third degree relationship would be siblings, an uncle and nephew, grandmother and grandchild, cousins etc.
Parkinson's disease (PD): Patients who are on at least 2 doses of L-dopa per day without optimal benefit can participate in an adjunct treatment protocol of a new dopamine agonist.
Parkinson's disease (PD): Patients whose medications are “wearing off” between doses or are experiencing other complications such as sialorrhea (drooling), dyskinesia, hallucinations, daytime sleepiness, delay from time medication is taken to onset of response, and freezing gait can participate in a variety of clinical trials designed to ameliorate these PD-related symptoms and L-dopa-related side effects.
Huntington Disease (HD): Patients with Huntington's disease or family members who are “at-risk” may qualify to participate in studies of the progression of the disease regardless of whether gene status is known or not.
Tourette Syndrome (TS): Patients with Tourette syndrome can participate in a variety of studies, including questionnaires designed to collect information about Tourette syndrome, family history and migraine headaches.